# A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

> **NCT07392736** · PHASE1,PHASE2 · RECRUITING · sponsor: **Advenchen Laboratories, LLC** · enrollment: 228 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** AL8326 tablets
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT07392736
- **Lead sponsor:** Advenchen Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-26
- **Primary completion:** 2029-11-07
- **Final completion:** 2029-11-07
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07392736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07392736, "A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07392736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*